Development of a rapid and high-performance chemiluminescence immunoassay based on magnetic particles for protein S100B in human serum

Luminescence

Volumn 28, Issue 6, 2013, Pages 927-932

  Zhang, Huisheng ^a   Qi, Suwen ^a   Rao, Jie ^a   Li, Qiaoliang ^a   Yin, Li ^a   Lu, Yuejun ^a  

^a SHENZHEN UNIVERSITY   (China)

Author keywords

chemiluminescence immunoassay; fluorescein 5 isothiocyanate; magnetic particles; N (aminobutyl) N (ethylisoluminol); protein S100B

Indexed keywords

BODY FLUIDS; CHEMILUMINESCENCE; COATED MATERIALS; IMMUNOLOGY; MONOCLONAL ANTIBODIES;

AMINOBUTYL; CHEMILUMINESCENCE IMMUNOASSAY; FLUORESCEIN ISOTHIOCYANATE; FLUORESCEIN-5-ISOTHIOCYANATE; HUMAN SERUM; ISOTHIOCYANATES; MAGNETIC PARTICLE; N-(AMINOBUTYL)-N-(ETHYLISOLUMINOL); PERFORMANCE; PROTEIN S100B;

DIAGNOSIS;

FLUORESCEIN ISOTHIOCYANATE; PROTEIN S100B; S100B PROTEIN, HUMAN;

ARTICLE; BLOOD; CHEMILUMINESCENCE IMMUNOASSAY; HUMAN; IMMUNOASSAY; LUMINESCENCE; MAGNETIC PARTICLES; MAGNETISM; N-(AMINOBUTYL)-N-(ETHYLISOLUMINOL); PARTICLE SIZE; TIME;

CHEMILUMINESCENCE IMMUNOASSAY; FLUORESCEIN-5-ISOTHIOCYANATE; MAGNETIC PARTICLES; N-(AMINOBUTYL)-N-(ETHYLISOLUMINOL); PROTEIN S100B;

HUMANS; IMMUNOASSAY; LUMINESCENCE; MAGNETIC PHENOMENA; PARTICLE SIZE; S100 CALCIUM BINDING PROTEIN BETA SUBUNIT; TIME FACTORS;

EID: 84890555798     PISSN: 15227235     EISSN: 15227243     Source Type: Journal    
DOI: 10.1002/bio.2461     Document Type: Article

References (29)

1. Moore BW,. Chemistry and biology of two brain-specific proteins, s-100 and 14-3-2. Adv Exp Med Biol 1972; 32: 5-7.
2. Marenholz I, Heizmann CW, Fritz G,. S100 proteins in mouse and man: from evolution to function and pathology (including an update of the nomenclature). Biochem Biophys Res Commun 2004; 322: 1111-22.
3. Kleinert K, Schleich F, Biasca N, Simmen HP,. Is there a correlation between S100 beta and post-concussion symptoms after mild traumatic brain injury? Zentralbl Chir 2010; 135: 277-8.
4. Espiga FR, Carrero JTV, Garcia MVP, Perez EM, Sanz MJR, Mena ER,. Usefulness of determining serum S-100 beta protein expression in screening patients with minor head injury in a hospital emergency department. Emergencias 2011; 23: 15-21.
5. Biberthaler P, Linsenmeier U, Pfeifer KJ, Kroetz M, Mussack T, Kanz KG, et al,. Measurement of S-100 for the indication of CCT in minor head injury: a multicenter trial on 1309 patients. Shock 2005; 23: 17.
6. Jastrzebska M, Chelstowski K, Siennicka A, Grzelec H, Bajer-Czajkowska A, Rybicka M, et al,. The character of haemostatic disorders and level of protein S-100 in acute ischaemic stroke can affect survival in the first week of follow-up: a pilot study. Blood Coagul Fibrinolysis 2011; 22: 388-95.
7. Povysil C, Kana R, Horak M,. S-100 protein positivity in osteogenic tumours and tumour-like bone forming lesions. Cesk Patol 2008; 44: 59-61.
8. Andres R, Mayordomo JI, Visus C, Isla D, Godino J, Escudero P, et al,. Prognostic significance and diagnostic value of protein S-100 and tyrosinase in patients with malignant melanoma. Am J Clin Oncol 2008; 31: 335-9.
9. Bottiger BW, Mobes S, Glatzer R, Bauer H, Gries A, Bartsch P, et al,. Astroglial protein S-100 is an early and sensitive marker of hypoxic brain damage and outcome after cardiac arrest in humans. Circulation 2001; 103: 2694-8.
10. Derwall M, Stoppe C, Brucken D, Rossaint R, Fries M,. Changes in S-100 protein serum levels in survivors of out-of-hospital cardiac arrest treated with mild therapeutic hypothermia: a prospective, observational study. Crit Care 2009; 13: R58.
11. Hachimi-Idrissi S, Van der Auwera M, Schiettecatte J, Ebinger G, Michotte Y, Huyghens L,. S-100 protein as early predictor of hospital of regaining consciousness after out cardiac arrest. Resuscitation 2002; 53: 251-7.
12. Townend W, Dibble C, Abid K, Vail A, Sherwood R, Lecky F,. Rapid elimination of protein S-100B from serum after minor head trauma. J Neurotrauma 2006; 23: 149-55.
13. Townend W, Ingebrigtsen T,. Head injury outcome prediction: a role for protein S-100B? Injury 2006; 37: 1098-108.
14. Kaca-Orynska M, Tomasiuk R, Friedman A,. Neuron-specific enolase and S 100B protein as predictors of outcome in ischaemic stroke. Neurol Neurochir Pol 2010; 44: 459-63.
15. Stranjalis G, Korfias S, Psachoulia C, Boviatsis E, Kouyialis A, Protopappa D, et al,. Serum S-100B as an indicator of early postoperative deterioration after meningioma surgery. Clin Chem 2005; 51: 202-7.
16. Vos MJ, Postma TJ, Martens F, Uitdehaag BM, Blankenstein MA, Vandertop WP, et al,. Serum levels of S-100B protein and neuron-specific enolase in glioma patients: a pilot study. Anticancer Res 2004; 24: 2511-14.
17. Jensen E, Sandstrom K, Andreasson S, Nilsson K, Berggren H, Larsson LE,. Increased levels of S-100 protein after cardiac surgery with cardiopulmonary bypass and general surgery in children. Paediatr Anaesth 2000; 10: 297-302.
18. Whitaker-Azmitia PM, Wingate M, Borella A, Gerlai R, Roder J, Azmitia EC,. Transgenic mice overexpressing the neurotrophic factor S-100 beta show neuronal cytoskeletal and behavioral signs of altered aging processes: implications for Alzheimer's disease and Down's syndrome. Brain Res 1997; 776: 51-60.
19. Burbaeva G, Kliushnik TP, Tsutsul'kovskaia M, Iankovich BD, Khorvat I,. Arthus reaction and delayed hypersensitivity reaction to nerve-specific proteins S-100 and 10-40-4 in schizophrenic patients. Zh Nevropatol Psikhiatr Im S S Korsakova 1986; 86: 103-5.
20. Rainer TH, Wong KS, Lam W, Lam NY, Graham CA, Lo YM,. Comparison of plasma beta-globin DNA and S-100 protein concentrations in acute stroke. Clin Chim Acta 2007; 376: 190-6.
21. Park ES, Park CI, Baek SY, Kim SW, Baek SK, Kim HO,. Serum immunoreactivity to S-100 in children with cerebral palsy and delayed development and in their healthy parents. Yonsei Med J 2000; 41: 328-32.
22. Rodriguez-Orozco AR, Ruiz-Reyes H, Medina-Serriteno N,. Recent applications of chemiluminescence assays in clinical immunology. Mini Rev Med Chem 2010; 10: 1393-400.
23. Zhang H, Qi S,. A rapid and sensitive chemiluminescence immunoassay based on magnetic particles for squamous cell carcinoma antigen in human serum. Clin Chim Acta 2011; 412: 1572-7.
24. Li ZY, Zhang QY, Zhao LX, Li ZJ, Hu GM, Lin JM, et al,. Micro-plate magnetic chemiluminescence immunoassay and its applications in carcinoembryonic antigen analysis. Sci China-Chem 2010; 53: 812-19.
25. Tian D, Duan C, Wang W, Li N, Zhang H, Cui H, Lu Y,. Sandwich-type electrochemiluminescence immunosensor based on N-(aminobutyl)-N-ethylisoluminol labeling and gold nanoparticle amplification. Talanta 2009; 78: 399-404.
26. Waitkins SA, Hookey JV,. The detection of leptospires by a chemiluminescent immunoassay. J Med Microbiol 1986; 21: 353-6.
27. Wojtczak-Soska K, Lelonek M,. S-100B protein: an early prognostic marker after cardiac arrest. Cardiol J 2010; 17: 532-6.
28. Shinozaki K, Oda S, Sadahiro T, Nakamura M, Abe R, Nakada TA, et al,. Serum S-100B is superior to neuron-specific enolase as an early prognostic biomarker for neurological outcome following cardiopulmonary resuscitation. Resuscitation 2009; 80: 870-5.
29. Heizmann CW,. S100B protein in clinical diagnostics: assay specificity. Clin Chem 2004; 50: 249-51.